596 related articles for article (PubMed ID: 30963600)
21. Genomic landscape and prognostic analysis of mantle cell lymphoma.
Yang P; Zhang W; Wang J; Liu Y; An R; Jing H
Cancer Gene Ther; 2018 Jun; 25(5-6):129-140. PubMed ID: 29755111
[TBL] [Abstract][Full Text] [Related]
22. How I manage mantle cell lymphoma: indolent versus aggressive disease.
Wilson MR; Barrett A; Cheah CY; Eyre TA
Br J Haematol; 2023 Apr; 201(2):185-198. PubMed ID: 36807902
[TBL] [Abstract][Full Text] [Related]
23. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.
Klener P
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500350
[TBL] [Abstract][Full Text] [Related]
24. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
[TBL] [Abstract][Full Text] [Related]
25. Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data.
Radhakrishnan VS; Lokireddy P; Parihar M; Prakash PS; Menon H
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1590. PubMed ID: 34821081
[TBL] [Abstract][Full Text] [Related]
26. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
27. Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.
Silkenstedt E; Dreyling M
Hematol Oncol; 2021 Jun; 39 Suppl 1():31-38. PubMed ID: 34105823
[TBL] [Abstract][Full Text] [Related]
28. Update on mantle cell lymphoma.
Maddocks K
Blood; 2018 Oct; 132(16):1647-1656. PubMed ID: 30154113
[TBL] [Abstract][Full Text] [Related]
29. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.
Jain P; Zhang S; Kanagal-Shamanna R; Ok CY; Nomie K; Gonzalez GN; Gonzalez-Pagan O; Hill HA; Lee HJ; Fayad L; Westin J; Nastoupil L; Hagemeister F; Chen W; Oriabure O; Badillo M; Jiang C; Yixin Y; Li S; Tang G; Yin CC; Patel KP; Medeiros LJ; Nair R; Ahmed S; Iyer SP; Thirumurthi S; Champlin R; Xu G; Tinsu P; Santos D; Wang R; Han G; Zhang J; Song X; Neelapu S; Romaguera J; Futreal A; Flowers C; Fowler N; Wang L; Wang ML
Blood Adv; 2020 Mar; 4(6):1038-1050. PubMed ID: 32191807
[TBL] [Abstract][Full Text] [Related]
30. Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy.
Girard J; Reneau J; Devata S; Wilcox RA; Kaminski MS; Mercer J; Carty S; Phillips TJ
Onco Targets Ther; 2019; 12():8003-8014. PubMed ID: 31686856
[TBL] [Abstract][Full Text] [Related]
31. Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions.
Gallucci Figorelle L; Galvão PT; de Lima FMR; Marimon P; Pentagna N; Milito C; Schaffel R; Carneiro K
Clin Lymphoma Myeloma Leuk; 2024 Jul; 24(7):433-445. PubMed ID: 38641485
[TBL] [Abstract][Full Text] [Related]
32. The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response.
Yuan S; Zuo W; Liu T; Fu H
Technol Cancer Res Treat; 2023; 22():15330338231208608. PubMed ID: 37880950
[No Abstract] [Full Text] [Related]
33. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
Hill HA; Qi X; Jain P; Nomie K; Wang Y; Zhou S; Wang ML
Blood Adv; 2020 Jul; 4(13):2927-2938. PubMed ID: 32598477
[TBL] [Abstract][Full Text] [Related]
34.
Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
[TBL] [Abstract][Full Text] [Related]
35. A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.
Bomben R; Ferrero S; D'Agaro T; Dal Bo M; Re A; Evangelista A; Carella AM; Zamò A; Vitolo U; Omedè P; Rusconi C; Arcaini L; Rigacci L; Luminari S; Piccin A; Liu D; Wiestner A; Gaidano G; Cortelazzo S; Ladetto M; Gattei V
Haematologica; 2018 May; 103(5):849-856. PubMed ID: 29472356
[TBL] [Abstract][Full Text] [Related]
36. [Mantle cell lymphoma: Towards a personalized therapeutic strategy?].
Navarro Matilla B; García-Marco JA
Med Clin (Barc); 2015 Jun; 144(12):553-9. PubMed ID: 25023849
[TBL] [Abstract][Full Text] [Related]
37. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024.
Ip A; Della Pia A; Goy AH
Clin Lymphoma Myeloma Leuk; 2024 Feb; ():. PubMed ID: 38493059
[TBL] [Abstract][Full Text] [Related]
38. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
[TBL] [Abstract][Full Text] [Related]
39. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.
Beà S; Valdés-Mas R; Navarro A; Salaverria I; Martín-Garcia D; Jares P; Giné E; Pinyol M; Royo C; Nadeu F; Conde L; Juan M; Clot G; Vizán P; Di Croce L; Puente DA; López-Guerra M; Moros A; Roue G; Aymerich M; Villamor N; Colomo L; Martínez A; Valera A; Martín-Subero JI; Amador V; Hernández L; Rozman M; Enjuanes A; Forcada P; Muntañola A; Hartmann EM; Calasanz MJ; Rosenwald A; Ott G; Hernández-Rivas JM; Klapper W; Siebert R; Wiestner A; Wilson WH; Colomer D; López-Guillermo A; López-Otín C; Puente XS; Campo E
Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18250-5. PubMed ID: 24145436
[TBL] [Abstract][Full Text] [Related]
40. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
